Latest COMPASS news

‘A change is in the air’ – ISAD 2019 symposium: Psilocybin therapy for treatment-resistant depression… the road to the clinic

It is estimated that 100 million people around the world suffer with depression that is not helped by existing medication. As a community, we need to do something about this. That’s why COMPASS brought together some of the world’s leading experts at the 2019 International Society of Affective Disorders (ISAD) conference in London to discuss the potential for psilocybin therapy in helping people with treatment-resistant depression.


The meeting was chaired by Professor Allan Young, Director of Kings College’s Centre for Affective Disorders, who was joined on a panel by Dr David Erritzoe of Imperial College, London, Catherine Bird and Dr James Rucker from King’s College London, and me, COMPASS Pathways’s Chief Medical Officer.


The need for innovation

The tone of the panel was set by Professor Young, who described the focus on revitalising the field of treating depression, and moving away from ‘another SSRI’, the class of drugs which, many believe, provides insufficient efficacy for many patients with depression. The audience was reminded of the history and neuroscience of psilocybin, how clinical research to date suggests a potential benefit in treatment-resistant depression, and the importance of ensuring the safety of those taking part in the current clinical trials that are actively enrolling patients.


Why set and setting is so important to psilocybin therapy

Of particular interest was our discussion on the importance of ‘set and setting’ during psilocybin therapy. Catherine Bird described the significance of context in a psychedelic treatment experience, how to run clinical trials when there’s no approved ‘model’, and managing this unconventional clinical approach in a safe way. Dr Erritzoe expanded on the effect of music during a psychedelic experience, sparking a debate about the subjectivity of music tastes and the potential for future investigators to be “more creative” about all elements of psilocybin therapy’s context.


Taking a traditional approach for a non-traditional drug

The positive discussion concluded with Dr Rucker attesting that there was “a change in the air” in reference to the number of studies now being conducted in psychedelic therapy, and stating his belief in the potential of psilocybin as a medicine. I reiterated that “the path forward is clear” with the need to complete a full clinical development programme with psilocybin therapy, to the highest standards. With fewer and fewer clincal trials being initiated for new drugs to tackle the unmet need in depression, I highlighted the importance of taking a “traditional approach for this non-traditional drug”.


We thank everyone who attended the meeting at ISAD, and especially our panel members and Chair for a great discussion. We hope it will have answered some of the questions around setting up trials in psilocybin therapy and explained why so many of us believe this is a highly promising innovation for mental health challenges like treatment-resistant depression.


-  Hans Eriksson, Chief Medical Officer, COMPASS Pathways



Welcome, Autumn interns!

As the nights draw in and the leaves begin to fall, COMPASS offers a warm welcome to our new Autumn interns! This season, we received many applications to our internship programme from a vast range of highly talented and passionate individuals. We are delighted to have such an enthusiastic and dedicated group on board who will contribute to our work in Research and Development, Business Development and Operations, and Therapist Training.

Find out more about our Autumn 2019 interns below:

Chandanee Mistry

Just completed a Masters in Molecular Genetics and Diagnostics at the University of Nottingham.


I really wanted to broaden my Intellectual Property knowledge to pursue a career as a Patent Attorney. Compass Pathways offered a great internship programme, company morals and well-supported environment.

If you could choose any person from history to be your best friend, who would you choose and why?
David Attenborough: Endless conversation and free holidays!

Bella Cameron

I recently completed my Masters of Law (LLM) at The University of Cambridge. Prior to that, I completed both a Juris Doctor and a Bachelor of Commerce at the University of Melbourne.


I thought an internship with COMPASS would be an exciting opportunity to learn more about both the science behind psilocybin therapy and the legal landscape in the field of new medical treatments. Additionally, I was attracted to work with a team of ambitious and forward-thinking people.

Fun fact:
I love art and have done courses in painting, print-making and ceramics. I am currently learning pottery!

Joanna Kuc

Just completed MSc Translational Neuroscience at Imperial College London, and hold a BSc in Pharmacology from Nottingham Trent University.


I am particularly fascinated by the nature of psychoactive substances and I believe that destigmatizing use of psychedelics could trigger a paradigm shift in psychiatry. Working for COMPASS allows me to pursue my interests in a dynamic team of open-minded individuals and contribute to making a positive difference which has a potential to affect numerous lives.

If you could choose any person from history to be your best friend, who would you choose and why?
Albert Hoffman, so he could tell me more about the “Bicycle Day”.

Laurie Medhurst

MSc Experimental Pharmacology and Therapeutics at UCL.


Compass seemed like the perfect opportunity to combine both my professional and academic interests in clinical trials, with my personal interest in mental health research. As I have various close connections who have been affected with TRD, I thought that working at COMPASS would be a great way to use my education to really contribute to the research and help those who are suffering from TRD.

If you were a wrestler, what would your entrance song be and why?
The Chain, Fleetwood Mac - because its a certified banger that will get anyone psyched up and ready.

Merve Atli

Clinical Neuropsychology at Leiden University.


I chose to do my internship at Compass Pathways because I really admire what everyone at Compass Pathways does. Working together with an amazing team on psilocybin therapy that can help a very large group of individuals, is very important to me. This does not only motivate me as an upcoming neuropsychologist, but it also gives me the opportunity to learn more about the human mind.

If you could possess any superpower, which would you choose and why?
Mind-reading – as a neuropsychologist, I would enjoy having an insight into how the brain really works!

Min Lee

Neurosciences with Business Management at Imperial College London.

South Korean.

I wanted to work for an interesting startup like COMPASS, with also a good will to improve access to mental health treatments with an innovative solution.

If you could possess any superpower, which would you choose and why?
The ability to convince anyone anytime on anything - to convince Pret that they should sponsor me.

Rachel Bellamy

MPhil in Medical Science (Psychiatry) at the University of Cambridge, having previously completed a Bachelor’s degree in Psychological and Behavioural Sciences there.


I think it is extremely important to do work that has wide-reaching, positive impact. COMPASS is at the forefront of innovation with the potential to hugely benefit many people, and I am very excited to work as part of the great team that helps deliver this.

If you could possess any superpower, which would you choose and why?
I would choose shapeshifting as you would never get bored. You could fly, fit into small spaces, turn into your favourite film character - the possibilities are endless!


COMPASS Pathways News | July 2019 Issue

Here are highlights of our activities in the first half of 2019 that we hope will move us closer to our goal of improving mental health care for as many as possible.

The resurgence in psychedelic research began two decades ago, with a handful of dedicated individuals and institutions studying the potential impact of substances such as psilocybin, MDMA and ketamine, in mental health care. Now, in 2019, psychedelic therapy is taking centre stage, with discussions on the subject taking place at high-profile global events such as TED and the World Economic Forum in Davos, as well as at mainstream healthcare and life sciences conferences.

We welcome this growing interest and are fortunate to collaborate and work with so many people who share our ambition of better care for those suffering with mental illness. Our commitment to our mission is as strong as it was when we began; we want to accelerate patient access to evidence-based innovation in mental health. Psychedelic research is a good place to start.

Treatment-resistant depression study in progress

Thirteen of our clinical trial sites are now active: we have three sites in the UK, three in the Netherlands, three in the USA, two in Spain, and one in each of Ireland and Canada. Further sites will be opening over the next few months. In total, our sites will be recruiting 216 patients with treatment-resistant depression, from across Europe and North America, to take part in this psilocybin therapy phase IIb trial.

As part of the trial recruitment process, potential participants are very carefully screened, by our trial sites and independent eligibility reviewers, to ensure their eligibility for the treatment. Our training of therapists is equally rigorous. We have now trained 65 therapists and assisting therapists in Europe, US and Canada. For a map of our current sites, click here.

Healthy volunteers study completed

We have completed our study of healthy volunteers, looking at the short- and long-term effects of medium and high dose psilocybin on social, emotional and cognitive functioning, compared with placebo. With 89 participants, this is the largest psilocybin study ever done. We are now processing the data and will be reporting full results later in the year.

Dr James Rucker, study clinician at King’s College London where the trial took place, said “To hear participants speaking afterwards about their deeply positive and heartfelt experiences was an emotional experience for me. ‘Blown away’, ‘profound and amazing’ and ‘years of the deepest psychotherapy’ were some of the phrases that come to mind. There was immense gratitude for the experience and for the attention to detail of the set-up and the study team.”

Investigator-initiated studies

In addition to progressing our own studies with psilocybin, we collaborate with select academic institutions and researchers, supporting research that could help patients and lead to a change in mental health outcomes. We provide our GMP (good manufacturing practice) psilocybin for these studies, free of charge, in exchange for the right to use the safety data generated. We are currently working or in discussion with 20 research teams on studies covering a broad spectrum of topics.

It is critically important that scientific research in this area continues, given the large unmet need in so many mental illnesses. At the same time, any innovation or breakthrough has to move out of the lab and into the reach of patients. We are committed to developing any promising results from early studies into the robust, large-scale research programmes required to generate the evidence needed by regulators, payers and health systems.

Funding our next phase of growth

We have raised $35 million to date, from a number of investors, all of whom are committed to our mission to improve patient access to innovation, and to see a shift in the way in which mental illness is treated and managed. We begin a further funding round later this month, and will use the money raised to drive our next phase of growth, operationally and in R&D. Our R&D work will include our own research, as well as any development programmes that emerge from our academic collaborations. Large-scale clinical trials require significant investment but are the only route by which we can move from innovation to patients.

Our team is expanding; we now have over 20 talented and committed people in our UK and US offices, as well as a thriving internship programme. This summer we welcomed interns from MIT, UPenn, UCL and Cambridge, working across different functions, including R&D, Clinical Operations, Patient Access, Business Development, and Technology.

We are already seeing the benefits of the Breakthrough Therapy designation that the FDA has given to our protocol of psilocybin therapy for treatment-resistant depression. FDA experts are helping us with our Clinical Development Plan for psilocybin therapy, as well as our plans for additional studies. And we are continuing to talk to payers, insurers, and patient advocacy organisations about patient access, and to explore ideas for how we make psilocybin therapy available to as many patients as possible.

While psilocybin therapy for treatment-resistant depression remains our priority and focus, our R&D team are also looking at other new compounds, innovative technologies and treatment modalities that might help patients for whom existing treatments don’t work. We are committed to bringing innovation to these patients as quickly as we can, and to understanding how we get people well and keep them well.

Your feedback

If you’d like to know more about what we are doing or have any comments about COMPASS Pathways News, please get in touch with us at

Welcome to Summer Interns

Summer is almost here and we are excited to give a warm welcome to our new interns at COMPASS Pathways! We were highly impressed with the experience and skills of our summer applicants. The interns will be contributing to our activities in various functions including marketing, research, and clinical trials operations.

Each brings their own unique skill set, and we can’t wait for them to add to our company’s success! Learn a little more about our Summer interns below:


     Simon Percelay

Studies: Masters in European Affairs at Sciences Po in Paris. I also hold a BA in Politics and Sociology from University of Cambridge.

Nationality: French.

Fun fact: I used to be able to read hieroglyphics.

Why COMPASS? I have a strong interest in depression as it has affected people close to me, and I chose to work at COMPASS because it gave me the opportunity to work in a field I'm interested in and for a goal that I believe in.

Rahul Sood


Studies: Neurobiology and Statistics at the University of Pennsylvania.

Nationality: New Zealand.

Fun fact: I am Eimear’s identical twin!

Why COMPASS? COMPASS is at the forefront of understanding novel, nuanced models of mental health and psychiatry. I consider it a privilege to be part of a team who are innovating in an area which desperately needs advancement.

     Eimear Monaghan

Studies: I just completed my first year of Graduate Medicine at the University of Dublin, and hold a Masters in Biochemistry from the University of Oxford.

Nationality: I identify as Irish, though I have lived in England my whole life.

Fun fact: I have an identical twin and we have been involved in the Twins Early Development Study since birth.

Why COMPASS? I believe that good health is the most valuable asset and I admire COMPASS’s drive to accelerate the process of translating research into practice. I am excited for this internship because I get to understand and be involved in this process.


     Kate Anna Roberts

Studies: MSc in Cancer Biology at UCL Cancer Institute, graduating this summer!

Nationality: British.

Fun fact: I used to work at a nature reserve as a teen, doing everything from preparing enclosures for injured bats to chopping logs for beetles to nest in. It’s also where I discovered a profound fear of grass snakes…

Why COMPASS? Getting the opportunity to work in such an innovative therapy area alongside an inspiring team with such a refreshing approach inspired me to apply to COMPASS and further motivates me every day.

     Mandy Ho

Studies: PhD in Experimental Psychology, UCL.

Nationality: Taiwanese.

Fun fact: I am a big fan of Yuval Noah Harari.

Why COMPASS? I am hoping to learn the important things that cannot be learned in labs – whether that’s implementing an idea or maximising impact on the world. COMPASS seems like a great place to learn these things as a high impact start-up that is trying to tackle one of the most significant issues in modern societies.

     Maksim Lavrov

Studies: MEng Biomedical Engineering at Imperial College London.

Nationality: Estonian.

Fun fact: I am a Tesla fan and I have a favourite country – the Netherlands.

Why COMPASS? I believe in the value that psilocybin can bring to patients and in COMPASS having the best shot at delivering it. I also want to take part in the psychedelic renaissance.


     Lena Zhu    

Studies: Major in Neuroscience and Biology, Minor in Biomedical Engineering at MIT.

Nationality: British.

Fun fact: I love tennis, painting and playing the ukulele.

Why COMPASS? I am passionate about improving mental health awareness and better access to treatment. Having seen close friends and family suffer from mental health illness, I want to be a part of the cutting edge of new treatment and innovation in this field.


     Eric Wehner

Studies: International Management at WHU Otto Beisheim School of Management.

Nationality: German.

Fun fact: When in Berlin on an election day, you might very well find me campaigning. I have been active in youth politics for six years.

Why COMPASS? COMPASS fascinates me because of its disruptive potential for mental healthcare. It breaks with a decade-old stigma and aims to improve the lives of millions of people by doing so. That commitment and its dedication made me join COMPASS.

     Kendra Terry     

Studies: I just completed Masters in Clinical Psychology at Columbia University Teachers College and will be starting my PhD at Adelphi in the same field this Fall.

Nationality: American.

Why COMPASS? I am excited to join COMPASS after having worked as a Research Assistant with Dr Elias Dakwarat Columbia Medical Center on a study using ketamine to treat cocaine and heroin addiction. I for as long as I can remember have been interested in understanding what is ‘special’ about the psychological mechanism triggered by psychedelics that allows people to see long-term changes in behavior.


      Jack Jones

Studies: Graduated from BA Filmmaking at Kingston University last year.

Nationality: Welsh.

Fun fact: As a child I was a professional actor and appeared in a few commercials!

Why COMPASS? I find learning about everything COMPASS does incredibly interesting! Helping those with mental health issues is a cause I’m very passionate about and believe the current pharmaceutical treatments available are inadequate, so it’s nice to work at a place where what they do really matters to me.


     Drummond McCulloch

Studies: Just completed a BSc in Pharmacology at the University of Glasgow, about to begin an MSc in Pharmacology at Hertford College, Oxford.

Nationality: British.

Fun fact: I am heading to the World University Powerlifting Championships in June to represent Team GB with the rest of the Glasgow Uni team. I also visit Norway every year and like to hitchhike around.

Why COMPASS? Through studying the pharmacology of typical antidepressants and experiencing friends’ struggles with mental health treatments, I am eager to help rework the world of mood disorder treatment and psychedelics seem very promising as it stands!

     Pei Lynn Tann

Studies: MPhil Translational Biomedical Research, University of Cambridge.

Nationality: Malaysian.

Fun fact: I used to train professionally in figure skating as a child.

Why COMPASS? I am interested in neuropsychopharmacology and am excited about the potential of unconventional therapies such as psilocybin in helping those who struggle with mental health issues.



  Aaron Potter 

Studies: MSci Chemistry at Imperial College London.

Nationality: British.

Fun fact: I have a black belt in Karate.

Why COMPASS? 300 million people’s lives are directly affected by depression worldwide but, the lives of the people around them are affected too. It’s exciting to be part of the team growing COMPASS; leading innovation into new therapies for mental health disorders and improving lives.


COMPASS Pathways News | December 2018 Issue

As 2018 draws to a close, we reflect on another busy year and share our highlights of the last few months with you.

We have continued to make good progress since our last update: beginning patient recruitment in five of our treatment-resistant depression trial sites; gaining approval and Breakthrough Therapy designation for our trial from the US Food and Drugs Administration (FDA); reaching the halfway point in our healthy volunteers study; securing £25m in funding; and convening the first meeting of our Scientific Advisory Board.

We receive emails from so many people who are suffering, or are close to someone who is suffering, with treatment-resistant depression. These stories motivate us all every day at COMPASS. Our mission – accelerating patient access to evidence-based innovation in mental health – remains critical while the incidence of depression and other mental health challenges continues to rise. More than 100 million people have treatment-resistant depression (TRD) and depression remains the leading cause of disability worldwide. We simply cannot ignore this and are determined to do our part in alleviating it. We remain focused on developing psilocybin therapy for the safe and effective treatment of patients with depression, for whom existing treatments do not work.

Treatment-resistant depression (TRD) trial

Our phase IIb clinical trial for psilocybin therapy for treatment-resistant depression has now been fully approved in the UK, the Netherlands, Canada, the US, and Ireland. Further approvals are expected in additional European countries over the next few months. Patient recruitment has begun in trial sites in the UK, the Netherlands, and Ireland.

Treatment room in TRD trial

In October, we held an Investigator Meeting and therapist training for our North American sites. These sites, across the US and Canada, will begin patient recruitment in the first quarter of 2019.

Breakthrough Therapy designation

In October, the FDA awarded Breakthrough Therapy designation to psilocybin therapy as a potential treatment for treatment-resistant depression. Breakthrough Therapy designation is given to therapies for which preliminary clinical evidence shows a potential substantial improvement over available treatments. This is a strong endorsement for the potential of psilocybin therapy and one that will increase the chances of getting this treatment to the many people suffering with treatment-resistant depression. The designation means the FDA will be committed to supporting our clinical development programme and will work closely with us to ensure the process is as efficient as possible.

Breakthrough Therapy designation is also a mark of recognition for the vision and extraordinary work of generations of psychedelic researchers and therapists before us.

Healthy volunteers study

Our healthy volunteers study is halfway through. The study is taking place at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London, and explores the short- and long-term effects of medium- and high-dose psilocybin on social, emotional and cognitive functioning, as compared to placebo. The study also provides a platform for therapists in our TRD trial to support volunteers under the guidance of our expert therapists, as part of their professional training.

We expect to complete the healthy volunteers study in the first half of next year and to report findings in the second half.


We have completed our Series A financing round, raising £25m from a group of investors who share our commitment to bringing Psilocybin Therapy to as many patients as possible. The funds will enable us to complete our healthy volunteers study and phase IIb trial.

Scientific advisory board

In November, we held the inaugural meeting of our scientific advisory board (SAB), a group comprising experts in neuroscience, psychiatry, neuropsychopharmacology, and regulatory science. With our SAB, we have begun to refine our clinical development plans and to explore ideas for additional studies in the future, to complement our work on treatment-resistant depression.

Looking ahead to 2019

Our progress and our achievements have been made possible by the dedication of our strong in-house team.

Our team continues to grow, and we are delighted that Hans Eriksson will be joining COMPASS in January as our new Chief Medical Officer. Hans was most recently Senior Director, Clinical Research for Depression and Pediatrics at H Lundbeck. He brings a wealth of experience in taking medicinal products to patients and we look forward to working with him as our clinical development programme continues. Ekaterina Malievskaia, COMPASS co-founder and current Chief Medical Officer, will take a more strategic role from 2019, overseeing R&D and our therapist training programme.

We enjoy a vibrant internship programme at COMPASS. This year we had 11 interns from leading European and US academic institutions, spending on average three months at COMPASS, and learning and contributing to different teams - from clinical trial management and operations, to market access, business development and fundraising. We will continue this programme in 2019.

In addition to our talented colleagues and enthusiastic interns, we are fortunate to work with an exceptionally skilled and dedicated group of advisors and partners. We are all excited about the next few months and each step that takes us closer to our goal of accelerating access to help patients.

In 2019, we will complete and report out on our healthy volunteers study. We also aim to complete recruitment for our treatment-resistant depression trial. While we are not pre-empting what the science will tell us or what the results of the trial will be, we have started the critical and complex work on market access strategy, so that we can be ready to bring psilocybin therapy to patients without delay and in a way that makes it accessible and affordable to as many people as possible.

In the spirit of the holiday season and on behalf of our board members, scientific advisors, investors and supporters, COMPASS has made a donation to One Mind, a US-based non-profit organisation dedicated to accelerating research in mental health though the principles of large-scale open science. We support and share their goals which are very much aligned to the work we are doing at COMPASS.

With only a few days left in 2018, we wish everyone a very happy holiday season, and all the best for the New Year. 

Your feedback

If you’d like to know more about what we are doing or have comments about COMPASS Pathways News, please get in touch with us at

Welcome to Fall Interns

Fall is here and COMPASS Pathways is thrilled to welcome new interns to the team!  We were impressed with the experience and skills of our fall applicants. After multiple rounds of interviews, six additions were made to our team. They have come from multiple universities and corners of the world, and we are excited to work with each of them! They are contributing to our activities in various functions including in marketing, research, and clinical trials operations.

Each brings their own unique skill set, and we can’t wait for them to add to our company’s success! Learn a little more about our interns below:


              Ali Mahomed


Hometown: Kingston upon Thames, UK
Favourite Food: Sashimi
BSc Statistics: London School of Economics and Political Science






              Candice Li 

Hometown: Changchun, China
Favourite Food: Matcha & Black Sesame Ice Cream
MSc Management: London School of Economics and Political Science
BA Business Economics: University of California, Los Angeles





              Nisha Thiara


Hometown: Leeds, UK
Favourite Food: Miso Pork Ramen
MSc Early Intervention in Psychosis: King's College London
BSc Psychology: University of Leeds





              Jade Raffle


Hometown: Suffolk, UK
Favourite Food: Sushi
PhD Cardiology and Genomics: Royal Veterinary College, U. of London
MSc Human Evolution and Behaviour: University College London
BSc Zoology: Queen Mary, U. of London




              Jake Jin-An


Hometown: Singapore, Singapore
Favourite Food: Fishball Noodles
BSc Actuarial Science: London School of Economics and Political Science






              Chloe Tan


Hometown: Kuala Lumpur, Malaysia
Favourite Food: Rice Krispies
LLB Law: London School of Economics and Political Science







Navigating Mental Health: COMPASS Pathways’ Psilocybin Research Program

Article written for the MAPS Bulletin Winter 2018

By Ekaterina Malievskaia, MD, MSc
Chief Medical Officer and Co-Founder


I first came to psychedelic research from a very personal experience with the limitations of psychiatry. I am a physician. George Goldsmith, my partner in life and business, has worked on complex regulatory and ethical issues of public-private collaboration. But despite our backgrounds, nothing prepared us for the devastation caused by the failure of the mental health care system when my son became ill. Even when the best doctors in the best institutions gave up on us, I kept looking for solutions. As we shared our story with friends and strangers, we realized that all of us are affected by the mental health crisis. And in the depth of our despair, we were still aware of how fortunate we were: we had resources and connections, and we could understand and assess the risks and benefits of emergent evidence for novel approaches. We resolved to make a difference for families who are in dire need of better treatments.

The early days

George and I were impressed by the vision and scientific rigor of the researchers at the Multidisciplinary Association for Psychedelic Studies (MAPS) and the Heffter Research Institute. Immediately after our first Heffter Board meeting in 2014, we offered not only financial support to the field, but help with regulatory strategy so that patients could benefit sooner. Despite significant challenges, we remain true to these commitments four years later.

In 2015, we created a US/UK non-profit, COMPASS, to support a pragmatic research project into psilocybin for psychological distress in hospice on the Isle of Man. Margaret Simpson, the visionary CEO of the hospice center, secured the support of the government, and together we received permission to train the first group of psychedelic therapists with psilocybin. There was only one obstacle: the psilocybin was not yet available from the Usona Institute or from the University of Wisconsin, both of which were also doing psilocybin research. Rather than wait, some of COMPASS’s Board of Trustees members recommended that we manufacture psilocybin ourselves. Given our mission, and uncertainty about the availability of psilocybin made under current Good Manufacturing Practices (cGMP), we followed their recommendation.

From its establishment in 2015 through its dissolution in 2017 (more on this later), COMPASS was 100% funded by George and me. No other donor funding was ever raised. We anticipated that if we followed the published process of synthesis, the cost of manufacturing would be in the range of £350,000 to £750,000 ($460,000 to nearly $1 million). We set out to create our supply for research in Europe. However, while we shifted our focus to the manufacturing of GMP psilocybin, the hospice CEO retired, the political leadership of the Isle of Man changed, and the opportunity passed.

The process of synthesis and formulation turned out to be much more complex and expensive than anticipated. We funded this work out of our personal funds, and the ever-rising cost was simply outside of our reach. That led George and me to seek legal advice to establish a drug manufacturing company eligible for tax credits under a UK government program that helps underwrite the cost of medicine research and development. That option, as well as other government incentives, is not available for non-profits. We formed that company, COMPASS Pathways Technologies Ltd, in June 2016.

In August 2016, Heffter researchers asked us to write a regulatory commentary on the upcoming publication of two landmark studies of psilocybin for cancer-related distress. Our advisor, the former head of the UK regulator, the Medicines and Healthcare products Regulatory Agency, Professor Sir Alasdair Breckenridge, agreed to do this. Heffter researchers also agreed for us to share the studies with the European Medicine Agency’s Scientific Advice Working Party in October 2016, a few weeks prior to the studies’ publication. The meeting with the EMA team was pragmatic, collaborative, and sobering. The regulators acknowledged the early evidence of efficacy, but encouraged us to focus on the indication of major depression instead. We shared the details of these discussions with both Heffter and Usona to help inform their regulatory strategy and further study designs.  

We took a sabbatical to consider our options. It was clear there were no political barriers to developing psilocybin as a medicine should the science meet regulatory standards. If we wanted to explore the therapeutic potential of psilocybin for depression, we were expected to take the traditional clinical development path, just like any other Investigational Medicinal Product (IMP). This meant we needed to go back to basics, starting with preclinical and simple dose-finding studies. It also meant the overall cost of development of psilocybin for the indication of depression would be over £100 million ($130 million).

We knew we would not be able to raise the necessary funds through donations since the clinical research was still in an early stage, and the indication of depression is among the most challenging ones. If we were to spend over £100 million on drug development, we wanted the solutions to be affordable, scalable and sustainable. In February 2017, we made the decision to establish a for-profit life sciences company. We renamed the for-profit drug development company to COMPASS Pathways. We started the process to wind-down the non-profit shortly thereafter. The only asset that we developed that had value following the EMA advice to focus on the indication of treatment resistant depression was the name and the branding work we commissioned. While this was of no value to anyone else, we purchased this asset for the same amount it cost to develop. This was independently reviewed and approved by the non-profit board of trustees.The non-profit was only funded by us personally and had no outstanding obligations to others, so the transition to for-profit was legally and logistically straightforward.

Manufacturing and patenting

While psilocybin is a naturally occurring molecule, psilocybin as an Investigational Medicinal Product or IMP is a regulatory entity that includes a detailed description of a GMP-compliant, scalable and reproducible manufacturing process; associated preclinical data; and ongoing safety data collected in clinical trials. The IMP can be thought of as a product’s fingerprint, so that regulators can recognize the safety and efficacy evidence gathered in the clinical trials as it relates to this unique product. The creation of an IMP is an extremely complex and expensive process that requires sustainable funding and a serious multi-disciplinary team effort. Based on our experience and the regulatory input from EMA, we now estimate that the development process will continue through marketing authorization and cost over £3 million (nearly $4 million).

In the process of synthesis, formulation and creation of preclinical data, we reached out to the researchers at Heffter and Usona with offers to share experience and ever rising cost, the last conversation being at PS17 in Oakland. Shortly after, the initial phases of the synthesis and formulation were completed, and psilocybin became the Investigational Medicinal Product.  From that point on, for the reasons of data consistency, there was no regulatory acceptable mechanism of “sharing” it other than through standard licensing agreements for the use of IMP. This is the way clinical research regulation works around the world.

As the previously published synthesis processes did not scale to meet regulatory standards, we had to invent our own process. As he would have done for anyone who would have asked for his help, David Nichols advised our manufacturing team. With his support our team has solved over 60 distinct technical problems in the synthesis and formulation process. Some of these inventions became the basis for our manufacturing patents. In general, patents provide an opportunity for an organization willing not only to take a significant financial risk to recoup the expenses, but more importantly, to ensure integrity of the data collected before and after the approval.

Our patents do not preclude others from creating a range of different solutions for the synthesis and formulation of psilocybin; nor do they preclude the use of naturally occurring mushrooms, extracts, or any other products created by alternative synthesis and formulation routes. Equally, our patents do not prevent other clinicians from using our product or any psilocybin-containing products in conjunction with the types of therapy or psychological support they judge to be helpful, as long as it does not jeopardize patient safety. Lastly, neither our patents, regulatory strategy, nor pricing strategy have an impact on the practices of the underground community of practitioners in nonclinical settings.

Our exclusive contract with the drug manufacturer does not prevent others from choosing among many different competing manufacturers through the standard Request for Proposal (RFP) process. The advances of science may now offer new creative solutions for the synthesis and formulation of psilocybin with new partners for those who are willing and able to spend the time, effort, and funds to create an alternative psilocybin-based IMP.  

While we have created the supply of psilocybin for our own research, we have made the unusual decision to share it with qualified independent researchers free of charge in exchange for being able to use their safety data. This is not a commercial decision, but yet another way to accelerate the generation of clinically relevant evidence that may ultimately improve patient outcomes.  

This process has proven to be challenging at times. As we have learned, university legal departments and technology transfer offices are vigilant about the potential Intellectual Property (IP) that might be created in the process of investigator-initiated studies. This IP, despite the best intentions of the researchers, does not belong to the scientists, who have limited say in how it is used by their institutions. In the event of IP creation, Technology Transfer Offices have a legal obligation to license it out to the ‘highest bidder’ with the most aggressive and scalable business model that will generate the most return for the academic institution. Even though such IP would be created by independent researchers with our IMP, in order to use the invention, we still have to compete with other commercial entities who might have different ethics or commercial goals.

This is an important consideration for the signatories of the Statement on Open Science and Open Praxis who work for academic institutions, as they need to align with their institutions on terms of IP licensing. The core principle of the statement is that knowledge created by signatories is open to all - that is, the knowledge is to be given away unconditionally by relinquishing researchers’ rights to protect it and to control who gets to use it after it becomes public.

We believe our patent strategy offers some protection against uses that may not be fully aligned with our mission to create access to innovative treatments for as many people as possible at an affordable cost to patients and healthcare systems.

Our focus: improving outcomes for the maximum number of people

Many people have asked us about our business model. Given that we are in the early stages of the development, the model is still evolving and will largely depend on the conditions of the regulatory approvals. In general, US law focuses on private companies maximizing value for shareholders only. UK corporate law is different: it requires us to create value for both shareholders and stakeholders. As a UK-based company, every COMPASS Pathways Board meeting starts with a reminder of this commitment.

Businesses might have different strategies to create value for shareholders. Charging high prices and stifling competition is one of them, but it is not the approach we plan to take. Instead, our goal is to provide broad access to all in need regardless of their ability to pay, creating greater value for health systems and translating to lower health insurance premiums and decreased healthcare cost. This is the approach our shareholders invested in and continue to support.

The high cost of clinical trials and drug development aside, the cost of manufacturing GMP psilocybin itself post-regulatory approval is likely to be relatively low. The future cost of psilocybin therapy will be determined at the point of care delivery by the treatment models, the services provided by the treatment centers, but mainly by the fees of individual providers.  The creation of reimbursable models of care then becomes essential if we are to ensure that everyone who would benefit from psilocybin therapy can access it regardless of their ability to pay. It might be that “a thousand flowers will bloom” – and eventually the best models will prevail simply through quality and price competition, or that treatments will be rolled out in a more regulated way. This will require constant feedback and frequent course correction, as we continue to learn from our collective experience.

One way to decrease this uncertainty and ensure the accessibility of the treatment is by engaging in frequent in-depth conversations with the regulators and payers early in the process, just as we suggested after our first Heffter Board meeting in 2014. This remains our main strategy today.

To date, we have had conversations with regulators in many different countries in Europe and North America. We have assembled hundreds of pages of detailed feedback on the clinical development of psilocybin for depression and other indications, and on regulators’ general views of the challenges and opportunities for the clinical development of psilocybin. We share these insights regularly with MAPS. We also offered to share our plans and experience with Usona and Heffter. However, we understand that the psychedelic community is facing many challenges as it grows and some might not consider these perspectives a priority at this time.

We realize now that we could have taken more time to communicate with researchers who supported us during our early non-profit stage. At that time, we simply assumed that we were all motivated by the urgent need to create safe, effective, and sustainable options for patients. In our drive to get things done, we may have unintentionally hurt some people by not communicating clearly enough about our intentions and decision process that led us to move from non-profit to profit and from a focus on existential distress in cancer patients to treatment-resistant depression. We sincerely regret this and intend to do a better job in the future. Today, many researchers have continued working with us, while others have chosen not to, citing their discomfort with a for-profit approach. We respect their choice.

We also appreciate that not everyone agrees with our model. We believe different models of care and organizational structure can co-exist, and we embrace healthy competition through creating alternative solutions. We also understand that in the diverse psychedelic community, there is a range of views on how to move forward. We appreciate the dedication, skills, and achievements of those who have chosen to work on legalization efforts, and we do not think our models are contradictory. In fact, arguments for decriminalization can be enhanced by the evidence generated in large-scale clinical trials conducted according to the highest regulatory standards. Regardless of the results of the trials, the individual patient experiences and extensive safety data collected and published in the process can be of significant value in helping change public and legislative opinions.  

The “elders” of psychedelic research have triumphed at what they set out to do. The world is paying attention, patients and clinicians are hopeful, leading research institutions are hosting conferences and developing research ideas, and institutional and private funders are willing and able to support further development. Scientists and clinicians now have a real chance to offer hope and help for millions of people suffering from psychological distress, regardless of their spiritual practices or ideological convictions.

The field of psychedelic research is entering a new chapter. This is both exciting and highly uncertain, as this work has never been done at scale and in full public view. Working in this historically sensitized and highly regulated space takes a wide range of skills, experience, sustainable funding, teamwork and collaborations across disciplines. With care and respect for differences of opinions, we know it is possible to have a constructive and thoughtful dialogue, and to collaborate in the interests of patients in need. We at COMPASS Pathways are committed to doing our part. We look forward to sharing lessons of successes and challenges with many of you in the future.

In the meantime, my son has recovered and now lives a happy and productive life. This was inconceivable just three years ago. Our story is not simply the story of a miracle cure, but the story of access to innovation, particularly for those who cannot afford it. We will have walked this challenging path so other families do not have to do so.

COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-Resistant Depression

For online press release, see:

COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its psilocybin therapy for treatment-resistant depression.

The FDA designates a drug as a Breakthrough Therapy if preliminary clinical evidence shows that it may demonstrate substantial improvement over available therapy. Breakthrough Therapies are supported by the FDA throughout the clinical development programme to ensure as efficient a process as possible.

Breakthrough Therapy designation is a significant milestone for psilocybin therapy and psilocybin research, and a testament to the work done over many years by research teams in the US, the UK and Switzerland. The Heffter Research Institute was the first to fund research in this field, and supported early studies at Johns Hopkins UniversityNew York University, and Harbor-UCLA. In the UK, the Medical Research Council backed the proof-of-concept study of psilocybin for treatment-resistant depression at Imperial College London in 2015. COMPASS Pathways is now running the first large-scale psilocybin therapy clinical trial for treatment-resistant depression, which will take place in Europe and North America over the next year or so.

George Goldsmith, Executive Chairman of COMPASS Pathways, said, "This is great news for patients. We are excited to be taking this work forward with our clinical trial on psilocybin therapy for treatment-resistant depression. The FDA will be working closely with us to expedite the development process and increase the chances of getting this treatment to people suffering with depression as quickly as possible."

Treatment-resistant depression is a huge unmet need, affecting 100 million people around the world who do not respond to existing treatments. Depression is one of the fastest growing health problems we face today, and the leading cause of ill-health and disability worldwide. The Breakthrough Therapy designation for psilocybin therapy highlights the importance of supporting early research that can be translated to clinically meaningful outcomes.

Dr Robin Carhart-Harris, Head of the Psychedelic Research Group, Imperial College London, said, "In our 2015 study, we provided psilocybin to 19 patients in a clinical setting, coupled with psychological support, and found promising signals of efficacy and safety as treatment for treatment-resistant depression. The Breakthrough Therapy designation is a strong endorsement for the potential of psilocybin therapy. We look forward to learning more as further clinical studies are carried out, by our team at Imperial College as well as in COMPASS's multi-centre trial."

Dr David Nichols, Chairman of the Board, Heffter Research Institute, said, "Since its inception in 1993, Heffter has been helping to design, review, and fund the early phase clinical studies on psilocybin at research institutions in the US and Europe. We are delighted that psilocybin is being recognised as a Breakthrough Therapy and look forward to continuing our work with researchers and partners around the world so that we can alleviate the suffering caused by mental illness."

About COMPASS Pathways

COMPASS Pathways is a life sciences company, founded in 2016 to accelerate patient access to evidence-based innovation in mental health. We are developing psilocybin therapy through a late-stage clinical trial in Europe and North America for patients with treatment-resistant depression. We will improve mental health through the development of new patient care pathways, based on advances in neuroscience, psychotherapy, psychopharmacology, and technology.


Tracy, +44-7966-309-024

COMPASS Pathways Receives FDA Approval for Psilocybin Therapy Clinical Trial for Treatment-Resistant Depression

For online press release, see:

COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for treatment-resistant depression. Regulatory approvals for the trial have already been given in the UK, the Netherlands and Canada.

The trial is a phase IIb dose-ranging study with 216 patients taking part in 12 to 15 research sites across Europe and North America. It will begin in the UK later this month and sites in other countries will join the trial as further regulatory approvals are received.

Psilocybin therapy combines a dose of psilocybin (a psychoactive medicine and the active ingredient in “magic mushrooms”) with psychological support, and has shown promising signals of efficacy and safety as treatment for depression in academic studies in the UK and US. If the trial is successful, it will be followed by phase III studies.

George Goldsmith, Chairman and Co-founder of COMPASS Pathways, said, “We are excited to be starting this landmark trial which has the potential to transform lives. Depression is the leading cause of ill-health and disability worldwide, and treatment-resistant depression affects more than 100 million people. It is a huge unmet need and the trial will teach us more about how this new approach might address it.”

Ekaterina Malievskaia, Chief Medical Officer and Co-founder of COMPASS, said: “The design of this study has been a truly collaborative effort, with scientists, clinicians, patient representatives and regulators from Europe and North America working together with the goal of helping patients suffering with treatment-resistant depression.“

About COMPASS Pathways

COMPASS Pathways is a life sciences company, founded in 2016 to accelerate patient access to evidence-based innovation in mental health. We are developing psilocybin therapy through a late-stage clinical trial in Europe and North America for patients with treatment-resistant depression. We will improve mental health through the development of new patient care pathways, based on advances in neuroscience, psychotherapy, psychopharmacology, and technology.


Tracy Cheung,, +44 7966 309024

COMPASS Pathways News | July 2018 Issue

This is the second of regular newsletters from COMPASS Pathways, highlighting recent and forthcoming events and developments that are relevant to us, our partners and healthcare system stakeholders.

It has been an incredibly busy time since the start of 2018. We are excited by the progress we have made across various areas, all of which promise benefits and hope for patients and their families. We have advanced our plans and preparations for our clinical trial on Psilocybin Therapy for treatment-resistant depression (TRD); and completed pre-clinical studies, which have provided compelling evidence on the safety of psilocybin therapy in animals and in-vitro models.

In addition, we have manufactured two batches of psilocybin, the equivalent of more than 20,000 doses of 25mg, to cGMP (Current Good Manufacturing Practice) standards to support regulatory assessments and our late-stage clinical trials; we are launching a psilocybin therapy study for healthy volunteers; and we have expanded our team and our board of directors.

About 100 million people suffer with TRD, and do not respond to existing treatments. In addition to the distress and suffering caused for individuals and their families, depression presents a severe cost burden for healthcare systems. Over the next few months, we will begin our TRD clinical trial in Europe and North America.

We’re building on the significant work that has already been done in this area, by gathering evidence in a larger population to see whether psilocybin therapy could provide a breakthrough to help patients suffering with TRD. If it does, we are committed to making sure as many patients as possible will benefit from the treatment.

In everything we do, we are guided by principles that put the patient first. They focus on delivering innovation and providing access to it, adhering to the highest standards of scientific rigour and integrity, and embracing openness and collaboration.

Our clinical trial on treatment-resistant depression

This trial will be a phase IIb dose-ranging study with 216 patients. The first patient will enter the trial in July or August in the UK. The trial will take place in 12 to 15 research sites across Europe and North America. If the trial is successful, it will be followed by phase III studies. Most likely these will compare the optimal dose to either placebo or standard of care.

Earlier this month, we held our first investigator and therapist training meeting at The Champalimaud Centre for the Unknown in Lisbon. This brought together more than 100 people from across Europe, who will be involved in managing the trial and working with patients. Over five days, the clinical teams reviewed the programme and protocol design, discussed recruitment and retention strategies, and received in-depth training to enable them to conduct the study to the highest levels of quality and consistency across research sites. Our clinical research partner, Worldwide Clinical Trials, was impressed by the unprecedented level of participation and commitment of the study teams. In his opening remarks, their president, Angelico Carta, described our partnership as “COMPASSion Worldwide”. We are excited to be working with Worldwide to bring this vision to life for patients.

Healthy volunteers study at Institute of Psychiatry, Psychology and Neuroscience (IoPPN)

In July, we are launching a study of the “Effects of psilocybin on cognition and emotional processing” at the IoPPN, King’s College London, in partnership with the University of Zurich, Switzerland and Cambridge Cognition. Ninety healthy volunteers will be randomised to receive placebo, 10mg or 25mg of psilocybin, administered simultaneously in up to six participants. The study will explore the effects of psilocybin on cognitive and emotional empathy, executive function, memory, attention and cognitive flexibility. In addition to scientific insights, it will provide a unique opportunity for therapists involved in psilocybin research to support psilocybin sessions alongside some of the most experienced researchers and clinicians from the US, UK and Switzerland. The study will run for 16 weeks from 23rd July.

Manufacture of cGMP psilocybin

Through a great collaboration with our manufacturing and formulation partners, we have manufactured two 250g batches of psilocybin, the equivalent of 20,000 doses of 25mg, to the highest regulatory standards (cGMP – current Good Manufacturing Practice). A large portion of this material is being used for stability testing to meet regulatory requirements. The remainder is now encapsulated, packaged and ready to be shipped to our trial sites. This will support our late-stage clinical trials in Europe and North America as well as independent investigator-led trials at leading academic sites on both continents.

Supporting independent psilocybin research

We are passionate about increasing access to treatments and options for patients, and furthering research that will improve mental health outcomes. So in addition to using our psilocybin for our own clinical trials, we are also making it available, free of charge, to members of the European College of Neuropsychopharmacology (ECNP) through its Medicines Chest programme. We are looking at extending this approach to other eligible scientific associations and researchers with approved protocols.

Psychedelic research in the news

There has been a real surge of interest in the potential of psychoactive medicines in recent months.

Two of COMPASS’s founders, George Goldsmith and Ekaterina Malievskaia, were guests on Rob Reid’s After On podcast and talked about their backgrounds and motivations, and the forthcoming treatment-resistant depression clinical trial.

Significant coverage has also been generated by a new book by Michael Pollan: “How to change your mind – what the new science of psychedelics teaches us about consciousness, dying, addiction, depression and transcendence.” COMPASS Pathways and our work are referenced in this book, as well as in an article Michael wrote for the New York Times Magazine in mid-May.

As a result, we are receiving numerous emails from patients and their families from all over the world. These messages inspire us to do all we can to develop and deliver accessible new treatment options for patients who are not helped by current medicines and therapies.

The importance of a sustainable business model

COMPASS Pathways is committed to accelerating patient access to evidence-based innovation in mental health. We want to develop and deliver medicines and therapies that can address significant unmet medical need (eg treatment-resistant depression) and then make sure they reach the patients who need them.

That is why we have decided to adopt a sustainable business model, in which we generate a reasonable profit to support and incentivise innovation. This strategy is already yielding important support for our research. For example, we have received our first R&D incentive payment from the UK government. As a private sector business, and based on our R&D investments, we will continue to receive these incentives which will enable us to fund more research. This virtuous cycle will encourage further private sector innovation in life sciences.

Drug development is a complex and costly process, particularly when it involves managing clinical trials and regulatory processes in multiple countries. We believe a balanced for-profit model, which aspires to deliver innovative therapies and enable patient access to them, is most likely to deliver the needed innovation on a long-term basis, which is critical to patients.

Our board of directors and scientific advisory board members

Our expanded board of directors has had its first meeting. Christian Angermayer, George Goldsmith and Ekaterina Malievskaia have been joined by three new independent directors. We welcome Annalisa Jenkins, who brings a tremendous amount of R&D expertise, having served as the Chief Medical Officer at Bristol Meyers Squibb and Head of R&D at Merck Serono; Thomas Lönngren who brings deep regulatory expertise, having led the European Medicines Agency for a decade; and David Norton who brings significant industry experience as former Company Group Chairman at Johnson & Johnson Pharmaceuticals and service on a number of boards.

We are also launching our scientific advisory board with leaders in neuroscience, psychiatry, regulatory science and health systems. They will be overseeing COMPASS's scientific research and clinical development programme to ensure we address the highest areas of unmet need with rigour and clinical equipoise. The members of the advisory board are:

Professor David Nutt MD PhD (Chairman)

  • Edmond J Safra Chair in Neuropsychopharmacology, Imperial College London
  • President, The European Brain Council
  • Former President of the European College of Neuropsychopharmacology

Professor Dr Elisabeth Binder

  • Director, Department of Translational Research of the Max Planck Institute of Psychiatry
  • Associate Professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine
  • Member, Board of Directors of the European College of Neuropsychopharmacology

Professor Sir Alasdair Breckenridge CBE FRSE

  • Former Chairman, UK Medicines & Healthcare products Regulatory Agency
  • Chairman, Centre of Regulatory Excellence Advisory Board

Thomas Insel MD

  • President & Co-Founder, Mindstrong Health
  • Former Lead, Verily Mental Health team
  • Former Director, US National Institute of Mental Health

Professor Zach Mainen PhD

  • Director of Neuroscience Programme, Champalimaud Centre for the Unknown
  • Leader of Systems Neuroscience Lab and founding director of International Neuroscience Doctoral Programme

Professor Luca Pani MD

  • Executive Director of Global Medical Innovation, NeuroCog
  • Former Director General, Italian Medicines Agency (AIFA)

Professor Diego Pizzagalli PhD

  • Director, Center for Depression, Anxiety and Stress Research; McLean Imaging Center; Laboratory for Affective and Translational Neuroscience
  • Professor in Department of Psychiatry, Harvard Medical School

Professor John Rush MD

  • Professor Emeritus, University of Texas Southwestern MC & Duke-NUS Graduate Med School
  • Recipient of Thomson Reuters: World’s Most Influential Scientific Minds (2014)
  • American Psychiatric Association: Award for Research in Psychiatry (2007)

Professor Paul Summergrad MD

  • Dr Frances S Arkin Professor and Chairman of Psychiatry Department, Tufts University School of Medicine
  • Past President, American Psychiatric Association

Your feedback

If you’d like to know more about what we are doing or have comments about COMPASS Pathways News, please get in touch with us at If you’d like to subscribe to our mailing list, you can do here any time.

Welcome to Summer Interns

Summer is here and COMPASS Pathways is thrilled to welcome new interns to the team!  We were impressed with the experience and skills of our summer applicants. After multiple rounds of interviews, five additions were made to our team. Our interns are part of the inaugural class of our internship program. They have come from multiple universities and corners of the world, and we are excited to work with each of them! They are contributing to our activities in various functions including in marketing, research, and clinical trials operations.

Each brings their own unique skill set, and we can’t wait for them to add to our company’s success! Learn a little more about our interns below:


              Anaïs Soula                  


Hometown: Anglet, France
Favourite Food: Her grandmother's home cooked food
PhD in Neuroscience: Bordeaux University
MA in Cellular and Molecular Biology: Bordeaux University
MA in Technology and Innovation Management: Paris-Sud University





             Claudia Sisa


Hometown: Pesaro, Italy
Favourite Food: Margarita Pizza
PhD in Neuroscience of Women's Health: UCL
MA in Biomedical and Neuromotor Science: University of Bologna
MA in Molecular Cellular and Developmental Biology: UCLA





    Nour Awad 


Hometown: Beirut, Lebanon
Favourite Food: Japanese
Associate Consultant at ZS Associates
Research Analyst at UNDP
MS in Environmental Health Engineering: Columbia University
BEng in Chemical Engineering: American University of Beirut
BSc in Chemical Engineering: McGill University




                Livia Ng


Hometown : Hong Kong
Favourite Food : Scotch Eggs
BSc in Neuroscience: UCL






          Johanna Fisher


Hometown : Villemoiron-en-Othe, France
Favourite Food : Cookies
Franklin Roosevelt Lycée



COMPASS Pathways News | December 2017 Issue


December 2017

Dear friends, supporters and colleagues,

The holiday season is approaching, and as we begin dreaming of festive treats and spending the holidays cocooned in thick duvets with a cup of hot chocolate in hand, I would like to reflect on our journey this past year and share a few 2017 highlights.

Trial designed by multidisciplinary team

In February, we held our treatment-resistant depression (TRD) trial design meeting at London’s Home House, assembling experts and leaders from the fields of psychiatry, pharma development, neuroscience and psychedelics. Those of you who were there will remember the spirit of collaboration and mutual learning, and how energised we all were by the novelty and promise of the approach.

EMA scientific advice completed

Only a few months later we presented our trial design and clinical development programme to the European Medicines Agency (EMA), at a scientific advice meeting led by the head Italian regulator and psychiatrist, Professor Luca Pani. We were impressed by how deeply European regulators were thinking about our proposed approach, and how well informed they were about these old, yet new compounds. The EMA’s thoughtful feedback and questions, on topics ranging from pre-clinical data to post-regulatory approval scenarios, led us to revise our protocol and clinical development plan and to develop strategies that will ensure our trial demonstrates safety and efficacy.

Clinical trial programme started

Our clinical trial programme is led by Sue Stansfield, a former global executive at inVentiv Health. Early in her career, Sue completed her PhD focusing on serotonin, and one of her first research projects was conducted in collaboration with Prof David Nutt. We have a strong partner in Worldwide Clinical Trials, our contract research organisation. Worldwide was selected for its commitment to innovation and focus on Central Nervous System (CNS) research. In our first six months of working together, the Worldwide team have demonstrated exceptional engagement, flexibility and resourcefulness. Together we have completed regulatory and ethics submissions in five countries, and have received positive initial feedback from ethics committees and health ministries. We are particularly excited that we have had our first clinical trial approvals, from the UK’s Medicines and Healthcare Products Regulatory Authority and the Dutch Ministry of Health. Well done and thank you to everyone involved!

Trial sites selected

In June we began to look for potential trial sites. We were encouraged by the wealth of psilocybin research knowledge that exists in some of the oldest and most established academic institutions in Europe, and among many of the most reputable researchers and clinicians in the field of mood disorders. Twelve sites in the UK, Norway, Finland, the Netherlands, Germany, Portugal, Spain and the Czech Republic have now been selected. We are delighted that Professor Guy Goodwin, former head of Psychiatry at Oxford University and former president of the European College of Neuropsychopharmacology, has agreed to be a coordinating Principal Investigator of our trial. Our COMPASS/Worldwide team has visited all the sites - a definite highlight of the last six months. To all the Principal Investigators and their teams, thank you for your enthusiasm and determination to overcome any and all challenges!

Patient experience at the core of our trial

We have been developing innovative patient preparation and therapist training models, essential components that will help to ensure the safety and success of the study. With considerable input and guidance from Bill Richards, Torsten Passie, Peter Gasser, and the excellent team at MAPS (Multidisciplinary Association for Psychedelic Studies), we are finalising the structure of the therapist training process for the first group of European therapists. This will use a web-based training platform, followed by three days of in-person training, and an apprenticeship with experienced psilocybin therapists at three European academic sites. We are fortunate to be working with two technology partners who share our vision. Longboat specialises in digital support for clinical trials, optimizing the flow of information between patents and study teams, and improving patients’ experience of research participation. Longboat will be hosting our digital patient preparation platform, showing animations and videos about psilocybin. Another partner, Mindstrong, will be collecting behavioural markers of depressive symptoms via a mobile application, with the ultimate goal of personalised care for depression.

cGMP (current Good Manufacturing Practice) psilocybin now available for research

This year, we have completed synthesis, formulation, stability testing, and all pre-clinical tests for psilocybin. Our psilocybin has made the transition from a research chemical to a medicinal product, ready to be approved upon successful completion of phase IIb/III trials in the EU and US.

The availability of cGMP-grade psilocybin has stimulated a lot of interest in the scientific community. COMPASS Pathways will provide psilocybin for investigator-initiated studies in at least nine countries across Europe, North America and Australia for psychiatric and medical indications, as well as experimental studies, free of charge. All participating sites will be contributing to the unified safety database which will help expedite approval and, ultimately, patient access.

Team growth

In addition to Sue Stansfeld, we have been joined by two new colleagues: John Boghossian, who is leading business and partnerships development, and Molly Lennard-Jones, our team coordinator. John graduated from MIT and the Harvard Business School and comes with experience in market access. Molly developed a strong interest in mental health after completing her research thesis on the role of personal narrative in PTSD among Holocaust survivors. Since September we have also been working with Chris Strutt and Tracy Cheung, formerly of GlaxoSmithKline and GE Healthcare respectively, who support us on public affairs and communications. We are fortunate to have such a talented and experienced group of people in the COMPASS team and our rate of progress has increased rapidly since they have been on board.

We have welcomed two new members to our advisory board: Dr Tom Insel, a neuroscientist and former head of the US National Institute of Mental Health; and Dr Paul Summergrad, the head of Psychiatry at Tufts University Medical School and former head of the American Psychiatric Association. We are deeply grateful to all of them and our ‘founding’ advisors - including Prof Sir Alasdair Breckenridge and Dr John Rush - for their continued support, expertise and wisdom.

Lastly, I want to express my thanks to two people without whom COMPASS Pathways would still have been a dream: Joe Heinen, our Chief Financial Officer, and Sarah Drummond, who makes all the important conversations and events happen.

Looking ahead

It has been a very busy year and 2018 is set to continue in the same way. A few key events:

With all the positive signals following our regulatory submissions, we are well positioned to enrol our first patient in March 2018. We expect to complete the enrolment for the dose finding phase of the study by the end of 2018.

A study of 50+ healthy volunteers is planned for Q2 2018. This study will explore the safety and effects of psilocybin on cognitive function and emotional processing. It will also begin to collect safety data on the simultaneous administration of psilocybin in groups of 5-10 volunteers. The study will be supported by psychiatrists experienced in group administration of psychedelics as well as by our therapists-in-training. It will be an excellent opportunity to start building a platform for shared knowledge and professional development for mental health professionals interested in the emergent field of psychedelic research and therapy.

A Pre-Investigational New Drug meeting with the FDA (US Food and Drugs Administration) is planned for January 2018. We plan to share the results of the EMA Scientific Advice with FDA and seek approval for the replication of the confirmatory phase of our TRD trial in the US.

We are always on the lookout for talent. With scientific rigour and patient experience at the core of our work, we plan to hire a lead for therapy research and training, early next year.

We continue to be humbled and inspired by the task ahead of us. We are immensely grateful for the enthusiasm and expertise that has been so generously shared by everyone involved. Thank you for all of your support, it has made such a difference to our work and will undoubtedly make a difference in patients’ lives.

I wish you the happiest of festive seasons and all the best for the New Year.

Kind regards,

Katya, on behalf of George, Lars and the COMPASS team